» Articles » PMID: 35314852

Harnessing Natural Killer Cells for Cancer Immunotherapy: Dispatching the First Responders

Overview
Specialty Pharmacology
Date 2022 Mar 22
PMID 35314852
Authors
Affiliations
Soon will be listed here.
Abstract

Natural killer (NK) cells have crucial roles in the innate immunosurveillance of cancer and viral infections. They are 'first responders' that can spontaneously recognize abnormal cells in the body, rapidly eliminate them through focused cytotoxicity mechanisms and potently produce pro-inflammatory cytokines and chemokines that recruit and activate other immune cells to initiate an adaptive response. From the initial discovery of the diverse cell surface receptors on NK cells to the characterization of regulatory events that control their function, our understanding of the basic biology of NK cells has improved dramatically in the past three decades. This advanced knowledge has revealed increased mechanistic complexity, which has opened the doors to the development of a plethora of exciting new therapeutics that can effectively manipulate and target NK cell functional responses, particularly in cancer patients. Here, we summarize the basic mechanisms that regulate NK cell biology, review a wide variety of drugs, cytokines and antibodies currently being developed and used to stimulate NK cell responses, and outline evolving NK cell adoptive transfer approaches to treat cancer.

Citing Articles

GPR132 regulates the function of NK cells through the Gαs/CSK/ZAP70/NF-κB signaling pathway as a potential immune checkpoint.

Hui X, Xue M, Ren Y, Chen Y, Chen X, Farooq M Sci Adv. 2025; 11(10):eadr9395.

PMID: 40043109 PMC: 11881902. DOI: 10.1126/sciadv.adr9395.


tumor cell engineering reverses immune escape to enhance immunotherapy effect.

Liu S, Yuan S, Liu M, Liu J, Fu S, Gao T Acta Pharm Sin B. 2025; 15(1):627-641.

PMID: 40041911 PMC: 11873609. DOI: 10.1016/j.apsb.2024.08.028.


The Multifaceted Roles of BACH1 in Disease: Implications for Biological Functions and Therapeutic Applications.

Wei X, He Y, Yu Y, Tang S, Liu R, Guo J Adv Sci (Weinh). 2025; 12(10):e2412850.

PMID: 39887888 PMC: 11905017. DOI: 10.1002/advs.202412850.


Effects of NK cell-related lncRNA on the immune microenvironment and molecular subtyping for pancreatic ductal adenocarcinoma.

Li J, Xia C, Li Y, Liu H, Gong C, Liang D Front Immunol. 2025; 15:1514259.

PMID: 39872533 PMC: 11770056. DOI: 10.3389/fimmu.2024.1514259.


Research Progress of NK Cells in Glioblastoma Treatment.

Wu H, Liu Q, Wang F, Gao W, Zhou F, Zhao H Onco Targets Ther. 2025; 18():87-106.

PMID: 39845286 PMC: 11752833. DOI: 10.2147/OTT.S486411.


References
1.
Robertson M, Stamatkin C, Pelloso D, Weisenbach J, Prasad N, Safa A . A Dose-escalation Study of Recombinant Human Interleukin-18 in Combination With Ofatumumab After Autologous Peripheral Blood Stem Cell Transplantation for Lymphoma. J Immunother. 2018; 41(3):151-157. PMC: 5847481. DOI: 10.1097/CJI.0000000000000220. View

2.
Mariotti F, Petrini S, Ingegnere T, Tumino N, Besi F, Scordamaglia F . PD-1 in human NK cells: evidence of cytoplasmic mRNA and protein expression. Oncoimmunology. 2019; 8(3):1557030. PMC: 6350684. DOI: 10.1080/2162402X.2018.1557030. View

3.
Kulkarni S, Martin M, Carrington M . The Yin and Yang of HLA and KIR in human disease. Semin Immunol. 2008; 20(6):343-52. PMC: 3501819. DOI: 10.1016/j.smim.2008.06.003. View

4.
Felices M, Kodal B, Hinderlie P, Kaminski M, Cooley S, Weisdorf D . Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL. Blood Adv. 2019; 3(6):897-907. PMC: 6436008. DOI: 10.1182/bloodadvances.2018029371. View

5.
Jing C, Fu Y, Yi Y, Zhang M, Zheng S, Huang J . HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1. J Immunother Cancer. 2019; 7(1):77. PMC: 6421676. DOI: 10.1186/s40425-019-0554-8. View